{"id":"hucb","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Engraftment failure or delayed engraftment"},{"rate":null,"effect":"Cytopenias"}]},"_chembl":null,"_dailymed":{"setId":"ee91d9e5-8129-4a81-acd3-8ce747f9cb2a","title":"NGF37 HUCB BOOST (NIACINAMIDE, ADENOSINE) LIQUID [CELINO INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"hUCB (human umbilical cord blood) contains hematopoietic stem cells and progenitor cells that can differentiate into various blood cell lineages. When infused, these cells engraft in the bone marrow and restore hematopoietic function, red blood cell production, platelet production, and immune cell populations. The therapy is used primarily as an allogeneic stem cell source for transplantation in patients with hematologic malignancies or bone marrow failure syndromes.","oneSentence":"hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:58.508Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant"},{"name":"Bone marrow failure syndromes"},{"name":"Severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT07339111","phase":"PHASE3","title":"Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis","status":"RECRUITING","sponsor":"Medipost, Inc.","startDate":"2026-03-11","conditions":"Knee Cartilage Defects","enrollment":300},{"nctId":"NCT02433509","phase":"PHASE1","title":"Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2015-05","conditions":"Acute Ischemic Stroke","enrollment":6},{"nctId":"NCT06040476","phase":"PHASE2","title":"Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)","status":"NOT_YET_RECRUITING","sponsor":"StemCyte, Inc.","startDate":"2025-09","conditions":"Acute Ischemic Stroke","enrollment":39},{"nctId":"NCT06377982","phase":"PHASE1","title":"Human Umbilical Cord Blood Infusion in Patients with Cerebral Palsy","status":"NOT_YET_RECRUITING","sponsor":"StemCyte Taiwan Co., Ltd.","startDate":"2025-09","conditions":"Cerebral Palsy","enrollment":12},{"nctId":"NCT03392467","phase":"PHASE2","title":"PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants","status":"COMPLETED","sponsor":"Medipost Co Ltd.","startDate":"2018-08-13","conditions":"Severe Bronchopulmonary Dysplasia","enrollment":60},{"nctId":"NCT03378063","phase":"EARLY_PHASE1","title":"Stem Cells for Bronchopulmonary Dysplasia","status":"WITHDRAWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2017-11-01","conditions":"Bronchopulmonary Dysplasia","enrollment":""},{"nctId":"NCT03172117","phase":"PHASE1, PHASE2","title":"Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.","status":"COMPLETED","sponsor":"Medipost Co Ltd.","startDate":"2017-05-19","conditions":"Alzheimer's Disease","enrollment":36},{"nctId":"NCT01988584","phase":"PHASE2","title":"Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-11","conditions":"Cerebral Palsy","enrollment":20},{"nctId":"NCT04725136","phase":"PHASE1, PHASE2","title":"Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2021-01-27","conditions":"Atopic Dermatitis","enrollment":96},{"nctId":"NCT04954534","phase":"NA","title":"Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM®","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-07-12","conditions":"Alzheimer's Disease","enrollment":9},{"nctId":"NCT02054208","phase":"PHASE1, PHASE2","title":"Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Medipost Co Ltd.","startDate":"2014-03","conditions":"Alzheimer's Disease","enrollment":46},{"nctId":"NCT04520022","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2016-10-13","conditions":"Recessive Dystrophic Epidermolysis Bullosa","enrollment":5},{"nctId":"NCT04234412","phase":"NA","title":"Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.","status":"UNKNOWN","sponsor":"Uijeongbu St. Mary Hospital","startDate":"2020-02-01","conditions":"Osteoarthritis, Knee","enrollment":10},{"nctId":"NCT04213131","phase":"NA","title":"Efficacy and Safety of hUC-MSCs and hUCB-MSCs in the Treatment of Chronic Spinal Cord Injury","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2018-01-01","conditions":"Spinal Cord Injuries","enrollment":42},{"nctId":"NCT03269773","phase":"PHASE3","title":"Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)","status":"COMPLETED","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2018-04-25","conditions":"Atopic Dermatitis","enrollment":197},{"nctId":"NCT02918123","phase":"PHASE1","title":"Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2018-01-17","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT02038972","phase":"PHASE1, PHASE2","title":"Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss","status":"COMPLETED","sponsor":"James Baumgartner, MD","startDate":"2013-01","conditions":"Sensorineural Hearing Loss","enrollment":11},{"nctId":"NCT02000362","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2014-08","conditions":"Crohn's Disease","enrollment":24},{"nctId":"NCT02926300","phase":"","title":"Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2015-11","conditions":"Crohn's Disease","enrollment":24},{"nctId":"NCT01626677","phase":"PHASE3","title":"Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect","status":"COMPLETED","sponsor":"Medipost Co Ltd.","startDate":"2012-06","conditions":"Degenerative Osteoarthritis, Defect of Articular Cartilage","enrollment":103},{"nctId":"NCT01927705","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2013-09","conditions":"Atopic Dermatitis","enrollment":34},{"nctId":"NCT02221258","phase":"PHASE1","title":"Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)","status":"COMPLETED","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":9},{"nctId":"NCT01696591","phase":"","title":"The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","startDate":"2012-03","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":14},{"nctId":"NCT01438593","phase":"PHASE1","title":"Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2013-01","conditions":"Ischemic Stroke, Ischaemic Cerebral Infarction, Infarction, Middle Cerebral Artery","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":614,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"hUCB","genericName":"hUCB","companyName":"StemCyte Taiwan Co., Ltd.","companyId":"stemcyte-taiwan-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery. Used for Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant, Bone marrow failure syndromes, Severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}